4 Interactions found for:

The following applies to the ingredients: Apixaban (found in Eliquis)

Professional Content

Use is not recommended.

AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned.

Risk Summary: Insufficient data exists to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes.

Comments:
-Treatment can cause uterine bleeding, that may require gynecological surgical intervention.
-Treatment can cause placental hemorrhage and subsequent fetal loss.
-This drug may increase the risk of bleeding in the fetus and neonate.
-Females of reproductive potential that require anticoagulation should discuss pregnancy planning options with their healthcare provider.

Animal studies have failed to reveal evidence of adverse developmental effects. There are no controlled data in human pregnancy.

Use of this drug during labor or delivery in women receiving neuraxial anesthesia may result in epidural or spinal hematomas.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

The following applies to the ingredients: Potassium Chloride

Professional Content

This drug should be used during pregnancy only if clearly needed. Use under physician supervision.

AU TGA pregnancy category: Exempt
US FDA pregnancy category: Not assigned

Comments:
-Pregnancy is associated with gastrointestinal hypomotility; solid forms of oral potassium should be given only if clearly needed.
-Close monitoring of serum potassium is recommended.
-Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm.

Animal studies showed no adverse effects on embryofetal development. There are no controlled data in human pregnancy. It is considered unlikely that supplementation that does not lead to hyperkalemia would adversely affect the fetus. The background birth defect and miscarriage risk for the indicated population is not known. In the US general population, the estimated major birth defect risk is 2 to 4% and the miscarriage risk is 15 to 20%.

AU Exempt: Medications exempted from pregnancy classification are not absolutely safe for use in pregnancy in all circumstances. Some exempted medicines, for example the complementary medicine, St John's Wort, may interact with other medicines and induce unexpected adverse effects in the mother and/or fetus.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

The following applies to the ingredients: Apixaban (found in Eliquis)

Professional Content

A decision should be made to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

The effects in the nursing infant are unknown.

Animal studies in lactation did not result in death of offspring. The drug was excreted in the milk of the animal model at a high milk to plasma ratio, possibly due to active transport.

The following applies to the ingredients: Potassium Chloride

Professional Content

Use is generally considered acceptable; benefit to mother should outweigh risk to the infant. Use under the supervision of a physician.

Excreted into human milk: Yes

Comments:
-As long as body potassium is not excessive, potassium supplementation should have little or no effect on the level in human milk.
-Normal potassium ion levels in human breast milk is about 13 mEq/L.
-There is no information regarding this drug on the effects on a breastfed infant or effects on milk production.
-Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for this medication as well as any potential adverse effects from this drug or the underlying maternal condition.